

ONE HEALTH – SOCIAL SCIENCES (OH-SS) ONLINE MEETING NOTES

Monday, June 11, 2018 10:00 AM-11:00 AM EDT

Goals for the Meeting:

- ✓ **REVIEW** achievements to date
- ✓ SHARE an experience crossing disciplines
 - Jerri Husch:
 "Action Leadership and Managing Complexity: Moving the OH Agenda Forward"
- ✓ **UPDATE** on work group activities
 - Publications
 - o Research
 - Mapping Project
- ✓ PLAN One Health Day Activity
- ✓ **IDENTIFY** next steps

Attendees:

- Laura Streichert and Lisa Webb (facilitators)
- Aisha Nankanja, Elizabeth Painter, Helena Chapman, Jerri Husch. Robert Blew, Wendy Rib

Recording Available at:

https://attendee.gotowebinar.com/register/6509170799696531458

Next Meetings:

We will host 2 meetings in July: 1. Monday, July 16, 2018, 10:00 am – 11:00 am EDT AND 2. Monday, July 16, 2018, 10:00 pm - 11:00-pm EDT

We hope this makes it easier for people to attend. Please sign up for one or both of the meetings here: For July 16, 2018, 10 am-11 am EDT: <u>https://attendee.gotowebinar.com/register/284049324852484611</u>

For July 16, 2018, 10 pm-11 pm EDT: https://attendee.gotowebinar.com/register/6457376106256662531

For your assistance, here is a handy link to a time zone converter http://www.thetimezoneconverter.com/



Audience Polls Is Flock working as our communication platform? Group Decision: Let's keep trying it. All new technologies have learning curves!

Meeting Goals and Agenda

- 1. REVIEW achievements to date
- 2. SHARE an experience crossing disciplines Jerri Husch: "Action Leadership and Managing Complexity: Moving the OH Agenda Forward"
- 3. UPDATE on work group activities
 - Publications
 - Research
 - Mapping Project
- 4. PLAN One Health Day Activity
- 5. IDENTIFY next steps



1. REVIEW achievements to date OH-SS 5th Meeting Work Groups Chair coordination and planning Flock groups being formed Members If you would like to join a workgroup, please send email to: ohss@onehealthcommission.org









































OH-SS Publications:

Goal: To communicate the relevance of integrating social sciences and OH, and to ______disseminate good practices, benchmarks, and success stories_____

Timeline

- May-Jun 2018
- Compile initial list of OH-SS journals and conferences Jun 2018
- Confirm initial list of OH-SS journals and conferences
- Jul-Aug 2018
- Prepare first drafts of publications





OH-SS Mapping Actors (MWG):

Goal: To establish a formal list of active social science stakeholders in OH education community practice and research, which can expand the current scope and increase the audience size of the OH community

Actions Completed

□Formed MAWG, based on disciplines and geographies, that can explore OH actors (N=16)

Compiled a list of OH-SS actors

Prepared a timeline for data collection





OH-SS Mapping Actors (MWG): Goal: To establish a formal list of active social science stakeholders in OH education, community practice and research, which can expand the current scope and increase the audience size of the OH community Timeline May 2018 Compile initial list of OH-SS stakeholders June 2018 Confirm initial list of OH-SS stakeholders Initiate "Pin Mapping" (OH Day / Who's Who) July 2018 Finalize "Pin Mapping"

OH-SS Mapping Actors (MWG):

Goal: To establish a formal list of active social science stakeholders in OH education community practice and research, which can expand the current scope and increase the audience size of the OH community

Table Summary

Geography:

France=2, Germany=2, Kenya=1, UK=5, USA=2

Disciplines:

-

Anthropology, Geography, Global Health, Medicine, Nursing, Philosophy, Public Health, Social Justice, Veterinary Medicine □Institution Type:

Academic=9, Private=1, Research institute=2

OH-SS Mapping Actors (MWG):

Goal: To establish a formal list of active social science stakeholders in OH education community practice and research, which can expand the current scope and increase the audience size of the OH community

Next Steps

The

Continue to expand the original document in Google Docs: https://docs.google.com/document/d/1qcsGUVnKUtnXsj3_YNB3yp9Of 4c2ZFd-4UefkdeE93c/edit?ts=5ae39a6b

□Initiate "Pin Mapping" (OH Day/Who's Who)

Research Work Group

- Aisha Nankanja
- · Wendy Rib

Z

- Strategies on how to engage members who expressed interest in the RWG
- Designing an internal research method with Questions and Probes to find out how we can use research to achieve the vision of the OH-SS initiative.







5. IDENTIFY next steps Next meeting: JULY 16, 2018, 10:00 am-11:00 am EDT (UTC-4) JULY 16, 2018, 10:00 pm-11:00 pm EDT (UTC-4) Look for message from work group chair(s) Look for information about Mission and OH Day Work Group Keep talking on Flock! Or by email to ohss@onehealthcommission.org

Lassa fever in Nigeria: the tale of a reactive health system

The World Report by Talha Burki (Feb 24, p 728)¹ described an unprecedented astronomical rise in Lassa fever cases in Nigeria, for which the first case was reported in 1969 and the epidemiology and endemicity are well understood. Failure of the Nigerian health system to prioritise preparedness activities has been detrimental for prompt control of Lassa fever, which requires robust laboratory facilities, trained health personnel, and coordinated epidemiological surveillance.² Therefore, we propose a four-pronged plan to ensure consistent and proactive preventive activities that could ameliorate the high proportion of fatalities and long-term debilitation observed in outbreaks of Lassa fever.

First, communities should be encouraged to take ownership of environmental protection and hygienic practices to control rodent invasion into urban dwellings and reduce rodent breeding areas,3 and to promptly refer cases with concerning symptoms to health facilities. Second, health authorities should prioritise annual training of health workers in the application of universal safety precautions for infection control and regular epidemic response drills, with periodic evaluations. Third, policy makers should provide a description of disease signs and symptoms in local languages, promote culturally appropriate health improvement practices, and publicise toll-free telephone lines for systematic reporting and surveillance. Fourth, the One Health approach^₄ should be applied to minimise human health risks by advocating for environmental sustainability, reduced bush burning practices, and preservation of vector habitats.

Federal commitment to empower collaborative participation of communities and leaders, develop policies that support health workers' safety, and promote health authorities' leadership in epidemiological surveillance could help establish robust preparedness activities that mitigate the burden of Lassa fever. Such action will inevitably transition the health system from reactive to proactive.

We declare no competing interests.

*Victor J Animasahun, Helena J Chapman drvictorani@gmail.com

3

Derriford Hospital, Plymouth Hospitals NHS Trust, Plymouth PL6 8DH, UK (VJA); and College of Medicine, University of Florida, Gainesville, FL, USA (HJC)

- 1 Burki T. Lassa fever in Nigeria: the great unknown. *Lancet* 2018; **391:** 728.
- Nicholson A, Reeve Snair M, Herrmann J, The National Academies of Sciences, Engineering, and Medicine. Global health risk framework: resilient and sustainable health systems to respond to global infectious disease outbreaks—workshop summary. Washington, DC: The National Academies Press, 2016.
- WHO. Lassa fever—Nigeria. March 23, 2018. http://www.who.int/csr/don /23-march-2018-lassa-fever-nigeria/en/ (accessed April 12, 2018).
- 4 Rabinowitz P, Kock R, Kachani M, et al. Toward proof of concept of a One Health approach to disease prediction and control. Emerg Infect Dis 2013; 19: e130265.

Dengue vaccination: a more ethical approach is needed

Since 2016, we have discussed the risks behind the recommendation and use in mass vaccination programmes of Dengvaxia-a dengue vaccine produced by Sanofi Pasteur (Lyon, France)-without immunological pretesting.^{1,2} By using differential equation models and statistical methods, my colleagues and I reassessed publicly available data from vaccine trials, and found a substantial reduction in the number of hospital admissions when Dengvaxia was given only to seropositive individuals (ie, those with a history of a previous infection from dengue virus), and a substantial increase in the number of hospital admissions over 5 years when administered without a previous population screening.³ More recently, we have found that an individual's serostatus before vaccination is the determinant of vaccine efficacy and its possible benefits.^{4,5} These findings eventually led the manufacturer to do a new analysis of the available trial data, resulting in WHO changing its recommendations on this vaccine in December, 2017.6 Our efforts were recently acknowledged in an Editorial in The Lancet Infectious Diseases.7 I therefore wish to respond to a recent Correspondence in The Lancet by Tikki Pang and colleagues (Feb 17, p 654),⁸ written on behalf of the Asia Dengue Vaccine Advocacy Group (which has received unrestricted educational grants from Sanofi Pasteur).

Pang and colleagues agree that the risk of severe disease in vaccinated children naive to dengue virus is real,8 as confirmed by Sanofi Pasteur on Nov 29, 2017.⁶ However, the authors also propose continuation of the mass vaccination programme, with physicians informing parents that "the potential benefits of vaccination far outweigh the potential risks for their child on the basis of factors such as the endemicity level where they live and the age of the individual".8 This approach is disturbing and unacceptable, especially after the latest public advice from WHO that "until a full review has been conducted, WHO recommends vaccination only in individuals with a documented past dengue infection".9

Pang and colleagues have also, fortunately, mentioned that a reliable laboratory testing method to detect previous exposure is needed, and suggested that it could be discussed and implemented. I agree with the authors that a reliable laboratory test is urgently needed to identify seropositive individuals; however, this vaccine should only be used after finding seropositivity, and it is definitely not suitable for a mass immunisation programme



Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/